Accessibility Menu
Io Biotech logo

Io Biotech(OTC) IOBT

Current Price$0.00
Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-100%
5 YearN/A
1 Year-100%
1 Month-51%
Io Biotech last closing stock price
MetricPriceDate
Last closeUSD 0.002026-05-07
Io Biotech stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-16.67%USD 0.002026-04-30
1 month-51.22%USD 0.012026-04-07
3 month-98.86%USD 0.352026-02-06
Year to date-99.34%USD 0.612025-12-31
1 year-99.59%USD 0.992025-05-07
3 year-99.8%USD 2.052023-05-08
Since inception-99.98%USD 15.652021-11-05

Io Biotech Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$88.35M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

$0.00

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

May 13, 2026

IOBT News

Foolcom-Featured.png

Io Biotech Posts Wider Loss in Q2

Motley Fool Markets TeamAug 14, 2025

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Io Biotech

IO Biotech develops cancer therapies that help the immune system fight tumors. Its main products aim to support patients with advanced cancers. The company’s treatments are designed for people with melanoma and other solid tumors.

What’s in the IO Biotech Toolbox?

  • IO102-IO103 (Cylembio): Cancer vaccine in late-stage trials for melanoma; targets immune-suppressing proteins in tumors. 0% of revenue, as the company is pre-commercial.
  • IO112: Vaccine in early development for cancers with high immune-suppressing cells; not yet generating revenue.
  • IO170: Preclinical vaccine targeting a protein linked to tumor growth; not yet in human trials.
  • Clinical Collaborations: Joint studies with Merck to test IO102-IO103 with pembrolizumab (an approved cancer drug).
  • Research and Development: All revenue and expenses are from developing these cancer immunotherapies; no commercial sales yet.

Growth Moves: IO Biotech’s Expansion Playbook

  • Launched global Phase 3 trial for IO102-IO103 with Merck in 2023.
  • Expanded pipeline with IO112 and IO170 in 2024 and 2025.
  • Secured $75.1 million private placement in August 2023.
  • Obtained €57.5 million loan facility from the European Investment Bank in December 2024.
  • Entered multiple clinical collaborations with Merck since 2022.

Why IO Biotech Catches the Eye

IO Biotech operates globally from Denmark, running clinical trials in several countries. Its T-win platform targets both cancer and immune-suppressing cells, aiming to improve treatment results. The company’s partnerships and regulatory designations help it stand out in the cancer therapy field.

Five Things You Need to Know

  • Revenue was $0 in Q2 2025, unchanged from Q2 2024 and Q2 2023.
  • Net loss was $48.6 million for six months ended June 2025, up 21.2% year-on-year.
  • Operating expenses reached $45.8 million in H1 2025, up 9.6% from H1 2024.
  • Cash and equivalents were $28.1 million as of June 30, 2025, down from $60 million at year-end 2024.

Bottom Line

IO Biotech remains focused on developing cancer immunotherapies, with no commercial products yet. The company faces ongoing losses and funding needs as it advances its clinical pipeline.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Headquarters

Copenhagen, 2200, DK

IOBT Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-591.35%

Return on Capital

-194.52%

Return on Assets

-142.70%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

-$910.00K

Operating Income

-$92.05M

EBITDA

-$87.26M

Operating Cash Flow

-$81.00M

Capital Expenditure

-$69.00K

Free Cash Flow

-$81.07M

Cash & ST Invst.

$30.66M

Total Debt

$1.46M

Io Biotech Performance Analysis

Io Biotech sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31N/A
Q12025-03-31N/A
Q22025-06-30N/A
Q32025-09-30N/A
Io Biotech sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31-33.3%
Q12025-03-3129.2%
Q22025-06-30-17.6%
Q32025-09-3067.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name
Q3 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$230.00K

-12.2%

Gross Margin

0.00%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

80

N/A

Net Income

-$8.38M

+65.1%

EBITDA

-$8.93M

+62.2%

Quarterly Fundamentals

Name
Q3 2025YOY CHG

Total Cash

$30.66M

-61.8%

Total Debt

$1.46M

-27.9%

Accounts Receivable

$991.00K

+2.8%

Inventory

$0.00

N/A

Long Term Debt

$1.33M

+0.7%

Short Term Debt

$788.00K

+13.5%

Return on Assets

-1.43%

N/A

Return on Invested Capital

-3.01%

N/A

Free Cash Flow

-$18.48M

+11.2%

Operating Cash Flow

-$18.48M

+11.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
HOWLWerewolf Therapeutics, Inc.
$0.37+0.63%
SPRBSpruce Biosciences, Inc.
$44.60-2.36%
ACETAdicet Bio, Inc.
$8.57+5.54%
OTLKOutlook Therapeutics, Inc.
$1.34-5.63%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$10.96-0.02%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$40.94+0.02%
TQQQProShares Trust - ProShares UltraPro Qqq
$70.28-0.02%
NOKNokia
$10.30-0.03%

Questions About IOBT

What is the current price of Io Biotech?

Io Biotech is trading at N/A per share.

What is the 52-week range for Io Biotech?

Over the past 52 weeks, Io Biotech has traded between N/A and N/A.

How much debt does Io Biotech have?

Io Biotech total debt is unavailable.

How much cash does Io Biotech have on hand?

Io Biotech does not have cash on hand data available.

What is Io Biotech’s dividend yield?

Io Biotech does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services